TrialAddressing Dementia Via Agitation-Centered Evaluation
Trial details
- Registry ID
- NCT03226522
- Phase
- Phase 2, Phase 3
Drug research
AXS-05
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Addressing Dementia Via Agitation-Centered EvaluationNCT03226522 | AXSM | Phase 2, Phase 3 | Completed | 2020-04-17Actual |
| A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease AgitationNCT05557409 | AXSM | Phase 3 | Completed | 2024-11-21Actual |
| Assessing Clinical Outcomes in Alzheimer's Disease AgitationNCT04797715 | AXSM | Phase 3 | Completed | 2022-11-21Actual |
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
Trial details
- Registry ID
- NCT05557409
- Phase
- Phase 3
Assessing Clinical Outcomes in Alzheimer's Disease Agitation
Trial details
- Registry ID
- NCT04797715
- Phase
- Phase 3
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |